Trials / Completed
CompletedNCT07342699
Location-Molecular Integrated Outcomes in 450 Cerebellar Glioma Microsurgical Cases
Microsurgical Outcomes and Prognostic Analysis of 450 Cases of Cerebellar Gliomas: Integrating Pathology, Molecular Biomarkers, and Novel Clinical Insights
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 450 (actual)
- Sponsor
- West China Hospital · Academic / Other
- Sex
- All
- Age
- 3 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to learn if refined anatomical location-combined with molecular biomarkers-can predict surgical success and long-term survival in 450 adults and children with cerebellar gliomas who underwent microsurgical resection at a single center between 2014 and 2024. The main questions it aims to answer are: 1. Does tumor location (cerebellar hemisphere, vermis, fourth ventricle, or pontocerebellar-angle region) independently influence extent of resection and overall survival after adjustment for WHO grade and molecular profile? 2. Among IDH-wild-type low-grade gliomas, does gross-total resection plus early adjuvant radiotherapy improve 5-year overall and progression-free survival compared with lesser resection or radiotherapy omission? Researchers compared four anatomical subgroups and multiple molecular subtypes (IDH, 1p/19q, MGMT, TERT, BRAF V600E) to quantify location-specific resection rates, complication rates, and survival outcomes. Participants underwent standardized pre-operative imaging, microsurgical resection with intra-operative monitoring when indicated, post-operative MRI within 48 h to quantify residual tumor, and longitudinal clinical and radiographic follow-up every 3-12 months for up to 10 years.
Conditions
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2024-01-01
- Completion
- 2024-06-01
- First posted
- 2026-01-15
- Last updated
- 2026-01-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07342699. Inclusion in this directory is not an endorsement.